None of these discoveries would be of much interest outside the lab were it not for some chance observations made in the early 1950s—that, for instance, an antitubercular drug that had induced an unexpected (although not unwelcome) euphoria inhibited an enzyme that breaks down serotonin, or that lysergic acid diethylamide (LSD), already famous for its profound effects on consciousness, has a chemical structure similar to serotonin. ❋ Gary Greenberg (2010)
In the next year, Roche, which had all but abandoned iproniazid as an antitubercular, sold the drug to four hundred thousand presumably happy, or at least less unhappy, customers. ❋ Gary Greenberg (2010)
Improvements in nutrition, hygiene and hospital care had kept the disease in almost steady decline throughout the first half of the century, and the free fall had continued since the advent of antitubercular drugs in the 1950s. ❋ Unknown (2008)
Six months of treatment with several antitubercular drugs (isoniazid, rifampin and pyrazinamide are the most common) costs under $300 and will almost always cure TB. ❋ Unknown (2008)
One reason TB-control programs are so important is that antitubercular drugs are such tricky instruments. ❋ Unknown (2008)
From Merck and Company, Inc., for a fellowship in the chemistry department for work on antitubercular compounds ❋ Unknown (1947)
In them changes take place that prove the specific antitubercular action of the remedy in a most surprising way. ❋ Max Birnbaum (1876)
The discovery and characterization of new drugs targeting key enzymes involved in essential mycobacterial biosynthetic pathways is paramount but without the introduction of novel lead compounds, such as platensimycin antitubercular therapy will not proceed fast enough to cope with the increasing resistance observed today. ❋ Alistair K. Brown Et Al. (2009)
(M. tb) severely limit the treatment options for tuberculosis (TB); hence, new antitubercular drugs are urgently needed. ❋ Garima Khare Et Al. (2009)
M. tb and thus represents an attractive target for the development of new antitubercular drugs. ❋ Garima Khare Et Al. (2009)
We believe that the findings of this study will provide valuable inputs in the development of inhibitors against the mymA operon, an important target for the development of antitubercular drugs. ❋ Garima Khare Et Al. (2009)
A few other mycobacterial Acyl-CoA Synthetases namely MenE (involved in menaquinone biosynthesis) and FAAL28 and FAAL19 (involved in Fatty acid metabolism) have also been targeted for the development of antitubercular drugs and small molecule inhibitors against these enzymes have been developed ❋ Garima Khare Et Al. (2009)
To gain further insight into the functioning of mymA operon, a potential target for developing antitubercular drugs, it is necessary to characterize its gene products., the last gene of the mymA operon, encodes a Fatty Acyl-CoA Synthetase. ❋ Garima Khare Et Al. (2009)
As part of SRI's strategic expansion of its TB research program, Dr. Sidharth Chopra recently joined SRI's Microbiology Program, having recently completed a Fellowship at Stanford University, conducting research on antitubercular drug discovery. ❋ Unknown (2008)
Dr. Chopra will help accelerate SRI's antitubercular research program. ❋ Unknown (2008)
[6] for its survival in the hostile environment, emphasizing the importance of its cell envelope constituents as targets for the development of new antitubercular drugs. ❋ Garima Khare Et Al. (2009)
